Literature DB >> 8037220

Two-versus three-sample method for estimating gentamicin pharmacokinetic values.

L A Lavezo1, R L Davis.   

Abstract

The performances of two-sample and three-sample methods for estimating gentamicin pharmacokinetic values were studied. The medical records of patients who had received a gentamicin dosage consultation at a Veterans Affairs medical center between June 1989 and May 1991 were reviewed. For each patient, the pharmacokinetics service had prospectively used three serum gentamicin concentrations (SGCs) determined from three blood samples taken during an initial gentamicin regimen to estimate gentamicin pharmacokinetic values and determine the alternative would achieve the desired SGCs. In the two-sample method, the authors retrospectively used the initial peak and trough SGCs determined from two blood samples to estimate pharmacokinetic values and establish an alternative regimen. The two methods were evaluated by comparing their results with each other and with the actual pharmacokinetic values determined from SGCs measured during the subsequent gentamicin regimen. A total of 27 patients (all men; mean age, 62 years) were included in the study. The two-sample and three-sample methods differed significantly in their estimates of elimination rate constant and half-life but not clearance, volume of distribution, or the daily dose needed to achieve the intended SGCs. Neither method produced estimates that differed significantly from the actual pharmacokinetic values. The three-sample method was less biased than the two-sample method in the prediction of trough SGCs. In middle-aged and elderly men, a two-sample method and a three-sample method of estimating gentamicin pharmacokinetics differed significantly only in the prediction of trough SGCs. The difference was probably not clinically important.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037220

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  1 in total

1.  Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient.

Authors:  F J Botha; P van der Bijl; H I Seifart; D P Parkin
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.